MedPath

Alligator Biosciences Announces Rights Issue to Fund Mitazalimab Development

Alligator Biosciences has finalized the terms for a SEK 280 million rights issue aimed at funding the development of mitazalimab towards phase 3, securing a partnership for the drug, and covering general corporate purposes. The subscription price is set at SEK 0.1 per unit, with the issue half-secured by subscription and underwriting commitments. The capital raised will also settle bridge loans and loans to Fenja Capital II.

Alligator Biosciences Finalizes Rights Issue Terms

Alligator Bioscience, a biotechnology company, has announced the specifics of its planned rights issue totaling SEK 280 million. The subscription price has been set at SEK 0.1 per unit, equivalent to SEK 0.01 per share. This strategic move is designed to bolster the company's financial resources for several key initiatives.

Key Details of the Rights Issue

  • Subscription Price: SEK 0.1 per unit (SEK 0.01 per share)
  • Unit Composition: Each unit includes ten ordinary shares, ten warrants TO 12, and five warrants TO 13.
  • Rights Allocation: One share grants 37 unit rights, with ten unit rights required to subscribe for one unit.
  • Market Context: The closing price prior to the announcement was SEK 0.2005.

Financial Implications and Use of Proceeds

If fully subscribed, the rights issue is expected to raise approximately SEK 281 million before issue costs. The proceeds are earmarked for several purposes:
  • Development of Mitazalimab: Advancing the drug towards phase 3 clinical trials.
  • Partnership and Pre-commercialization Activities: Securing a partnership for mitazalimab and preparing for its market introduction.
  • Corporate and Restructuring Costs: Covering general corporate expenses and restructuring efforts.
  • Debt Settlement: Repaying bridge loans and loans to Fenja Capital II.

Subscription and Underwriting Commitments

Approximately 6% of the rights issue is covered by subscription commitments, with an additional 44% secured through underwriting commitments. This ensures that the issue is half-secured, providing a solid foundation for the fundraising effort.

Timeline

  • Last Trading Day with Preferential Rights: January 23
  • Subscription Period: January 29 to February 12
This rights issue represents a pivotal step for Alligator Biosciences in its quest to advance mitazalimab through critical development phases and secure its position in the competitive pharmaceutical landscape.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

BioVersys Announces IPO to Fund Phase 3 Trials for BV100 and Alpibectir

BioVersys AG, a clinical-stage biopharmaceutical company, plans to go public on the SIX Swiss Exchange in Q1 2025, aiming to raise CHF 80 million. The funds will primarily support the Phase 3 clinical development of BV100, targeting carbapenem-resistant Acinetobacter baumannii infections, and the ongoing development of alpibectir for tuberculosis. This move underscores the company's commitment to addressing antimicrobial resistance, a critical global health challenge.

AnaCardio Raises SEK 205 Million and Reports Positive Phase 1b Data of AC01

AnaCardio, a portfolio company of Karolinska Development, has successfully raised SEK 205 million and announced positive results from its Phase 1b clinical trial of AC01. Karolinska Development, a Nordic life sciences investment company, focuses on advancing medical innovations into commercial products that aim to improve patients' lives while offering attractive returns to shareholders.

Marvel Biosciences Announces $2.5 Million Private Placement to Advance MB-204 Clinical Trials

Marvel Biosciences is set to conduct a non-brokered private placement, offering common shares at $0.15 each, aiming to raise up to $2.5 million.
The raised capital is primarily allocated to cover the deposit for Phase 1 clinical trials of Marvel's lead compound, MB-204, alongside general operational expenses.

Arch Biopartners Establishes Australian Subsidiary for Metablok Phase I Trial in Acute Kidney Injury

Arch Biopartners has created Arch Clinical Pty Ltd in Australia to facilitate a Phase I safety trial for Metablok, a drug candidate targeting acute kidney injury.
The Phase I trial application has been submitted to the Alfred Health Human Research Ethics Committee, with a decision anticipated in early 2019.

KALA BIO Secures $10.75M Private Placement to Advance Rare Eye Disease Treatment

KALA BIO has secured $10.75 million in private placement funding from institutional investors to advance KPI-012, its lead candidate for persistent corneal epithelial defect (PCED). The company's Phase 2b CHASE trial is over 80% enrolled, with topline data expected in Q2 2025, potentially serving as one of two pivotal trials needed for BLA submission.

Pharming Group to Acquire Abliva in $66.1 Million Deal, Bolstering Mitochondrial Disease Pipeline

Pharming Group N.V. has announced a public cash offer to acquire Abliva AB for approximately US$66.1 million, strengthening its pipeline.
Abliva's lead product, KL1333, is in a pivotal clinical trial for primary mitochondrial disease (PMD) driven by mitochondrial DNA mutations.

Intensity Therapeutics Secures $3 Million to Advance Cancer Therapies

Intensity Therapeutics has secured $3 million through a direct stock offering and private placement to bolster its working capital.
The funds will support ongoing clinical trials, including a Phase 3 trial for soft tissue sarcoma and a Phase 2/3 program for triple-negative breast cancer.

Sareum Holdings Raises £2.4 Million to Advance TYK2/JAK1 Inhibitor SDC-1801

Sareum Holdings has successfully completed a £2.4 million fundraise to support the development of its lead asset, SDC-1801.
The funding will facilitate longer-term toxicology studies, preparing SDC-1801 for Phase 2 clinical trials in autoimmune diseases.

Cardiff Oncology's Onvansertib Enters Phase 2 Trial for KRAS/NRAS-Mutated Metastatic Colorectal Cancer

Cardiff Oncology has initiated a Phase 2 randomized trial (ONSEMBLE) of onvansertib in patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC).
The company's Scientific Advisory Board (SAB) has been expanded with full membership, enhancing expertise for clinical development.

Scandion Oncology Announces Rights Issue to Raise Approximately SEK 60 Million

Scandion Oncology has announced a rights issue aiming to raise approximately SEK 60 million, with the potential to secure up to SEK 306 million. The initiative is designed to fund the company's continued development, particularly the CORIST trial for metastatic colorectal cancer, and to prepare for a larger randomized study. The rights issue is subject to approval at the annual general meeting on 6 May 2024.

Reference News

[1]
Alligator Biosciences has nailed down the subscription price in the rights issue
marketscreener.com · Jan 20, 2025

Alligator Bioscience announced a SEK 280 million rights issue, with a subscription price of SEK 0.1 per unit. The capita...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy